跳转至内容
Merck
CN

SML1103

恩替卡韦

≥98% (HPLC), Nucleic acid synthesis inhibitor, powder

别名:

2-氨基-1,9-二氢-9-[（1S，3R，4S）-4-羟基-3-（羟甲基）-2-亚甲基环戊基] -6H-嘌呤-6-酮, 2-氨基-9-[（（1S，3R，4S）-4-羟基-3-羟甲基-2-亚甲基-环戊基] -3,9-二氢嘌呤-6-酮, BMS 200475, SQ 34,676

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C12H15N5O3
化学文摘社编号:
142217-69-4
分子量:
277.28
UNSPSC Code:
51111800
PubChem Substance ID:
329825478
NACRES:
NA.77
MDL number:
MFCD11046562

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

恩替卡韦, ≥98% (HPLC)

SMILES string

O=C1C2=C(N([C@H]3C[C@H](O)[C@@H](CO)C3=C)C=N2)NC(N)=N1

InChI

1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1

InChI key

QDGZDCVAUDNJFG-FXQIFTODSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +25 to +40°, c = 0.2 in H2O

storage condition

desiccated

color

white to beige

solubility

H2O: 0.5 mg/mL, clear (warmed)

storage temp.

−20°C

Quality Level

100

相关类别

Biochem/physiol Actions

恩替卡韦是一种抗病毒鸟嘌呤类似物，可在病毒复制过程中抑制逆转录、DNA复制和转录。 恩替卡韦可用于治疗乙型肝炎。
恩替卡韦是一种抗病毒鸟嘌呤类似物，可抑制逆转录、DNA复制和转录。
恩替卡韦被用作治疗慢性乙型肝炎病毒（CHB）携带的拉米夫定难治性患者的有效药物（每日1 mg剂量）。

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H351

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000341185
0000341185
0000397849
0000283684
0000245721

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Lei Jiang et al.
PloS one, 11(1), e0147440-e0147440 (2016-01-23)
Nucleoside analogues (NAs) have been the most frequently used treatment option for chronic hepatitis B patients. However, they may have genotoxic potentials due to their interference with nucleic acid metabolism. Entecavir, a deoxyguanosine analog, is one of the most widely
Li-Ting He et al.
World journal of gastroenterology, 22(46), 10210-10218 (2016-12-29)
To investigate the efficacy of switching to pegylated interferon-α-2a (PegIFNα-2a) treatment in nucleos(t)ide analog (NA)-treated chronic hepatitis B (CHB) responder patients. A 48-wk prospective and retrospective treatment trial of NA-treated CHB patients who had received entecavir (ETV) for at least
Wei Wei et al.
Cancer communications (London, England), 38(1), 61-61 (2018-10-12)
The optimal strategy for adjuvant therapy after curative resection for hepatocellular carcinoma (HCC) patients with solitary tumor and microvascular invasion (MVI) is controversial. This trial evaluated the efficacy and safety of adjuvant transcatheter arterial chemoembolization (TACE) after hepatectomy versus hepatectomy
Entecavir therapy for lamivudine?refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M, et al.
Hepatology, 48(1), 99-108 (2008)
Yunjian Zeng et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 24(4), 1414-1419 (2019-10-28)
To investigate the therapeutic effect of 125I seed implantation combined with chemotherapy and antiviral therapy on hepatitis B virus (HBV)-related liver cancer. A total of 126 patients with HBV-related liver cancer were selected and divided into observation group (n=63) and
查看所有相关文献

商品

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持